|
Near term focus is to maintain progress with LAX-101 for Huntington's disease. We expect an additional U.S. Phase III clinical ...
LAX-101 is a novel and proprietary product being developed for treatment of the symptoms of Huntington's Disease (HD). LAX-101 has ...
Amarin announced today that it has completed a private placement of 6,093,727 ordinary shares to a group of accredited investors ...
Fast track approval of LAX-101 for the treatment of Huntington's disease. Market for LAX-100 estimated at $500,000,000 ... ...
Questions and answers about LAX-101, the first statistically significant treatment for Huntington's disease in phase 3 clinical trials. ... ...
Amarin Corporation Announces Encouraging Preliminary Results of LAX-101 Pivotal Study in Huntington's Disease ... ...
We knew it all along. HD is a treatable condition. LAX101 is expected be available in the first half of ...
LAX-101 and NPLs Demonstrate Benefit in the Treatment of Huntington's Disease in Separate Phase II Studies..Monash study was halted on ...
LAX-101, pure ethyl eicosapentaenoate (EPA), is in trial for the treatment of HD. LAX-101 is manufactured by Laxdale in the ...
We at Laxdale follow with great interest all that is posted on the HD Lighthouse Website. We thought you would ...
Show all Updates for this
section listed by Date
|